Type 2 diabetes mellitus and osteoarthritis by Veronese, Nicola et al.
Seminars in Arthritis and Rheumatism 49 (2019) 919
Contents lists available at ScienceDirect
Seminars in Arthritis and Rheumatism
journal homepage: www.elsevier.com/locate/semarthritType 2 diabetes mellitus and osteoarthritisNicola Veronesea,*, Cyrus Cooperb,c,d, Jean-Yves Reginsterd,e,f, Marc Hochbergg,h,u,
Jaime Brancoi, Olivier Bruyered,e, Roland Chapurlatj, Nasser Al-Daghrif, Elaine Dennisonb,
Gabriel Herrero-Beaumontk, Jean-Franc¸ois Kauxl, Emmanuel Maheum, Rene Rizzolid,n,
Roland Rotho, Lucio C. Rovatip,q, Daniel Uebelhartr, Mila Vlaskovskas, Andre Scheent
a National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy
bMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK
c NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK
dWHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liege, Belgium
eDepartment of Public Health, Epidemiology and Health Economics, University of Liege, CHU Sart Tilman B23, 4000 Liege, Belgium
f Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
g Division of Rheumatology & Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
h Geriatric Research, Education and Clinical Center, Baltimore, MD, USA
i CEDOC, NOVA Medical School, Universidade Nova de Lisboa, Department of Rheumatology, CHLO, Hospital Egas Moniz, Lisbon, Portugal
j INSERM UMR 1033, Universite de Lyon, Ho^pital E Herriot, 69437 Lyon cedex 03, France
k Department of Rheumatology, Bone and Joint Research Unit, Fundacion Jimenez Diaz, Universidad Autonoma, Madrid, Spain
l Department of Physical & Rehabilitation Medicine and Sports Traumatology, SPORTS2, FIFA Medical Centre of Excellence, University and University Hospital of
Liege, 4000 Liege, Belgium
m Rheumatology Department, AP-HP, Saint-Antoine Hospital, 4 Blvd. Beaumarchais, 75011 Paris, France
nDivision of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
oMax-Reger-Strasse 17-19, 45128 Essen-Suedviertel, Germany
p School of Medicine and Surgery, University of Milano  Bicocca, Milan, Italy
q Department of Clinical Research, Rottapharm Biotech, Monza, Italy
r Division of Musculoskeletal, Internal Medicine and Oncological Rehabilitation, Department of Orthopaedics and Traumatology, Ho^pital du Valais (HVS),
Centre Hospitalier du Valais Romand (CHVR), CVP, Crans-Montana, Switzerland
sMedical University Soﬁa, Medical Faculty, Department of Pharmacology, 2, Zdrave str., 1431 Soﬁa, Bulgaria
t Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Department of Medicine, University of Liege, CHU Liege, Sart Tilman B35,
B-4000 Liege, Belgium
uMedical Care Clinical Center, VA Maryland Health Care System, Baltimore, MD, USAA R T I C L E I N F OAbbreviations:MetS, metabolic syndrome; NAFLD, Non-alc
non-steroidal anti-inﬂammatory drug; T2DM, type 2 diabete
* Corresponding author.
E-mail address: nicola.veronese1@aulss3.veneto.it (N
https://doi.org/10.1016/j.semarthrit.2019.01.005
0049-0172/© 2019 The Authors. Published by Elsevier InA B S T R A C T
Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist,
along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower
limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may
play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest.
Methods: We conducted a critical review of the literature to explore the association between T2DM and OA,
whether any association is site-speciﬁc for OA, and whether the presence of T2DM impacts on OA outcomes.
We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM.
Results: T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-
grade chronic inﬂammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk fac-
tor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety
concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non-
steroidal anti-inﬂammatory drugs, and corticosteroid injections, while other anti-OA medications may be
safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid.
Conclusions: Future research is needed to better understand whether diabetes control and prevention can
modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with
T2DMmay require careful consideration of the evidence based to avoid untoward safety issues.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are com-
mon diseases that are predicted to increase in prevalence [1,2]. OA
and T2DM frequently co-exist simply by chance due to their high
prevalence and shared risk factors. For example, the association of OA
with obesity is well-supported [3], and obesity occurs in the majority
of people with T2DM [4,5]. Aging is a well-known risk factor for both
T2DM and OA. The estimated prevalence in the US of T2DM is 4.6 mil-
lion among individuals aged 1844, and rises to 14.3 million people
aged 4564 and 12.0 million people aged 65 years [6]. Similarly,
radiographically-deﬁned knee OA increases dramatically with age,
affecting 14% of adults aged over 25 years and 37% of those over the
age of 60 years [7].
T2DM is a highly prevalent complex disease with a genetic back-
ground and the intervention of environmental risk factors, especially
poor lifestyle habits that lead to overweight and obesity. The preva-
lence of the disease markedly increases with age, with >10% of the
population aged 65 years having T2DM. The disease combines sev-
eral defects, among which include a defect in insulin secretion by
pancreatic beta-cells, and cellular insulin resistance mainly present in
skeletal muscles and the liver but also in other tissues [8,9]. Pro-
longed hyperglycemia, both in fasting and postprandial states, leads
to advanced glycated end products (AGEs), oxidative stress and low-
grade inﬂammation, and results in damage to the vessels, mainly in
the heart, kidneys, eyes, nerves, but also other tissues [10].
Nearly half (47.3%) of patients with T2DM have some form of
arthritis [11]. OA is a heterogeneous disorder affecting joints of the
hand, hip and knee. Beside the various localizations, different pheno-
types of OA have been proposed that include age-related, metabolic
syndrome (MetS)-related (closely linked to abdominal adiposity),
genetic-related, and post-traumatic OA [12,13]. In MetS-associated
OA, the mechanical impact of overweight/obesity on joints may easily
explain lower limb OA [14]. Other components of MetS, including
dysglycemia (that may be considered as equivalent to a prediabetic
state), high blood pressure and atherogenic dyslipidemia may
together or independently participate in OA pathophysiology
[1517]. Of note, more than three-quarters of patients with T2DM
have MetS according to the unifying deﬁnition [18]. So far, the sever-
ity of symptomatic knee OA is found to be signiﬁcantly associated
with hypertension, dyslipidemia, and the number of MetS factors
present; although no association between the severity of radio-
graphic knee OA and MetS factors was found in the same study [19].
In this critical literature review, we seek to explore whether T2DM
is linked to OA outside of weight overload and whether T2DM may
play a role in OA pathophysiology. The consequence of T2DM on OA
outcomes is also a question of research interest. There are multiple
pharmacologic treatment options available which may provide ade-
quate management of the symptoms of OA. However, evidence is
mounting for safety concerns with some of the most frequently pre-
scribed anti-OA medications, including paracetamol and non-steroi-
dal anti-inﬂammatory drugs (NSAIDs) [2023]. In addition, we have
reviewed the available evidence to explore whether the co-presence
of T2DM poses any additional safety issues for the treatment of OA.
Methods
Articles included in this narrative review were identiﬁed through
literature searches of PubMed using the following MeSH items or free
words: “osteoarthritis”, “type 2 diabetes mellitus”, “incidence”, “pro-
gression”, “epidemiology”, “pathophysiology”, “antidiabetic agent”,
“paracetamol”, “NSAIDs”, “SYSADOA”, “corticosteroid”, “hyaluronic
acid”, “bariatric surgery”. The search strategy was limited to studies
conducted in humans, publications in English language, and full-
length articles published from inception until January 15, 2018. A
similar search was made in Scopus, EMBASE and Google Scholar inorder to ﬁnd relevant studies in this ﬁeld. Finally, the reference lists
of relevant articles (particularly review articles) were scrutinized for
potentially interesting articles.
Incidence and progression of OA in people with T2DM
An association between the occurrence of T2DM and OA has been
demonstrated, although a causal link is not well established. In a
meta-analysis of 49 studies involving more than 1 million partici-
pants (N = 1192,518), Louati et al. found that OA and T2DM were sig-
niﬁcantly associated [14]. The odds ratio (OR) of T2DM in the OA
population vs. non-OA population was 1.41 (95% CI 1.21, 1.65), and
the prevalence of T2DM among patients with OA was 14%. The overall
presence of OA in the T2DM population vs. non-T2DM population
(OR) was 1.46 (95% CI 1.08, 1.96). In this population (mean age 61
years), the prevalence of OA among patients with T2DM was 30%
(38% hand OA, 12% hip OA, and 17% knee OA) [14]. In another meta-
analysis including only studies controlling for weight or body mass
index (BMI), the presence of OA in patients with T2DM was also high,
with an OR of 1.25 vs. non-T2DM population (95% CI 1.05, 1.46) [24].
Data for an association between T2DM and site of OA gives vari-
able outcomes; an association between T2DM and hand OA is found
in some studies and a meta-analysis [14,3]. The association is robust,
especially for younger patients: those aged 5562 years with T2DM
had a two-times higher rate of hand OA than non-diabetics, which
was associated with pain in erosive hand OA [25,26]. However, a
recent case-control study using a UK population-based database of
people aged 3090 years found no signiﬁcant association between
T2DM and hand OA, although the number of OA and/or diabetic
patients may have been underestimated due to diagnostic uncertain-
ties [27]. The association between diabetes and erosive hand OA war-
rants further investigation.
T2DM may be a risk factor for OA progression; T2DM is found to
be a risk factor for disease progression in men with established knee
OA based on annual assessment of joint space narrowing (JSN), while
no relationships were found between MetS or other metabolic factors
and radiographic progression [28]. T2DM is an independent risk pre-
dictor for arthroplasty. After controlling for age, BMI, and other
potential confounders, the presence of T2DM doubles the risk of
severe OA necessitating arthroplasty (HR = 2.1; 95% CI 1.1,3.8;
p = 0.023). T2DM was associated with more severe clinical symptoms
of OA and structural joint changes [29].
Conversely, in a population-based case-control study (N = 94,609),
no association was found between DM (almost 20 times more T2DM
than type 1 diabetes in this cohort) and total joint replacement (TJR)
of either the hip or knee among OA patients with or without DM [24].
T2DM may have a negative impact on arthroplasty outcomes includ-
ing an increased risk of post-surgical death, decreased functional out-
comes for arthroplasty, increased rate of infection, and increased
need for revision arthroplasty [10]. Some arthroplasty outcomes may
pertain to metabolic effects on joint tissues such as defective bone
healing, while others reﬂect general risks of T2DM associated with
major surgical procedures, while all can add considerable cost to clin-
ical care [10].
Could anti-diabetic medications be important?
Whether anti-diabetic medications impact on OA outcomes has
been investigated in an analysis of longitudinal data from the Osteo-
arthritis Initiative study, ﬁnding that medication-treated diabetes has
no effect on knee OA incidence (OR = 0.53; 95% CI 0.23, 1.5), but
reduces knee OA progression, measured as JSN or knee replacement
therapy (OR = 0.66; 95% CI 0.440.98) [30].
Metformin is the ﬁrst recommended antidiabetic drug for the
management of T2DM. In a UK cohort study set within the Consulta-
tions in Primary Care Archive, of 3217 patients with T2DM, there was
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and OA outcome during follow up (adjusted HR = 1.02; 95% CI: 0.91,
1.15) [31]. However, in a case-control study performed in Taiwan,
patients who have OA and T2DM receiving combination NSAIDs and
metformin therapy had lower joint replacement surgery rates than
those without metformin (adjusted HR = 0.742; 95% CI 0.601, 0.915;
p = 0.005) [32]. It has been suggested that this effect may be attribut-
able to a reduction in pro-inﬂammatory factors associated with com-
bined therapy with metformin. Indeed, metformin and even more
thiazolidinediones are antidiabetic agents that have been shown to
exert some anti-inﬂammatory activity [33]. However, a large popula-
tion based case-control study was performed in UK using the Clinical
Practice Research Datalink; it did not ﬁnd any evidence for a disease
modifying osteoarthritic effect of thiazolidinediones [34], despite
promising results from animal in vivo studies [34]. Finally, there are
no clinical data available yet with new antidiabetic agents such as
incretin-based therapies - dipeptidyl peptidase-4 (DPP-4) inhibitors
and glucagon-like peptide-1 (GLP-1) receptor agonists or sodium-glu-
cose cotransporter type 2 (SGLT2) inhibitors.Pathophysiology of OA and association with diabetes
OA is a complex disease affecting all joint tissues of articular carti-
lage, subchondral bone, and synovium. OA is associated with a local
and systemic low-grade inﬂammation state [35]. Articular cartilage
comprises an extracellular matrix containing chondrocytes, responsi-
ble for synthesis of the extracellular matrix. One role of cartilage is to
absorb the mechanical stresses between two mobile bone surfaces; in
OA the stress is followed by an increase of pro-inﬂammatory media-
tor production by chondrocytes, including cytokines (interleukin-1b
[IL-1b]), tumor necrosis factor-a (TNF-a), radical oxygen species,
AGEs, and prostaglandins. This local inﬂammation induces an
increase in production of proteolytic enzymes (matrix metalloprotei-
nases [MMPs] and aggrecanases) that will digest the cartilage matrix.
T2DM has a pathogenic effect on OA through 2 major pathways:
(1) Chronic hyperglycemia, which induces oxidative stress, overpro-
duction of pro-inﬂammatory cytokines and AGEs in joint tissues; and
(2) Insulin resistance, which could play a role locally but also through
the systemic low-grade inﬂammatory state [35]. Leptin, a major adi-
pokine secreted mostly by adipose tissue, is able to promote chondro-
cyte apoptosis and also increase cytokine and MMP production by
chondrocytes [36]. An insulin-resistant state and obesity are also
associated with elevated free fatty acids (FFAs), which may modulate
OA progression [37].
Role of insulin/insulin resistance
The role of insulin on OA remains controversial, especially because
high insulin levels are associated with insulin resistance in T2DM, so
that it is not easy to distinguish between the effects of insulin per se
and the effects related to insulin resistance [38,39]. Human chondro-
cytes express functional insulin receptors that respond to physiologic
insulin concentrations. The insulin receptors seem to be more abun-
dant in normal than in OA chondrocytes, and some responses are
impaired while others appear fully activated [40]. It has been sug-
gested that excess insulin as seen in T2DM patients may damage
cartilage.
In immortalized human chondrocytes and cultures of primary
human chondrocytes, it is found that insulin downregulates autoph-
agy by reducing LC3 II expression and increasing Akt and rpS6 phos-
phorylation. Autophagy is an essential homeostasis mechanism in
articular cartilage, that is defective in T2DM and OA. Loss of proteo-
glycans and increased MMP-13 and IL-1b expression was observed
after insulin treatment. Furthermore, chondrocytes from diabetic
patients with OA showed decreased LC3 and increased p-rpS6expression compared to healthy subjects and non-diabetic OA
patients [41].
Insulin resistance and T2DM are often a consequence of visceral
obesity, which is an important source of pro-inﬂammatory cytokines,
causing low-grade chronic metabolic inﬂammation that can lead to
structural damage in the joints [42]. Insulin resistance might impair
joint tissue because of a local insulin resistance of diabetic synovial
membrane [43], but also by the systemic low-grade inﬂammation
state [35]. The synovium is shown to develop insulin resistance in
obese OA patients with T2DM [44]. Insulin is a critical negative regu-
lator of synovial inﬂammation and catabolism, and the development
of insulin resistance in obese individuals would diminish the ability
of insulin to suppress the production of inﬂammatory and catabolic
mediators that promote OA [43].
The systemic role of MetS associated with insulin resistance in OA
pathophysiology is now better understood, but new avenues of
research are being pursued to better decipher the insulin resistance/
MetS-associated OA phenotype [45].
Diabetes and cartilage/chondrocytes
Cartilage is a non-vascularized and non-innervated tissue and
receives nutrients from its connection with subchondral bone and
synovial ﬂuid through joint cavity. Chondrocytes are glycolytic
cells that express glucose transporters (GLUT) (especially GLUT-1,
GLUT-3 and GLUT-9) and are able to sense glucose concentration in
the media and adapt GLUT expression under normal conditions
[46]. The capacity of chondrocytes to adapt themselves to local glu-
cose level is lost during OA, which is responsible for high glucose
uptake and potential glucose toxicity [47]. Local high glucose con-
centration leads to a reduction in chondrogenic differentiation of
mesenchymal, muscle, and adipose-derived stem cells, which may
further decrease the potential regeneration of cartilage that is
already decreased in OA [35].
Chronic high glucose environment also has a noxious effect on
chondrocyte metabolism. High glucose concentration has a pro-
inﬂammatory and pro-degradative effect on human OA chondrocytes.
AGEs are known to accumulate in cells and tissues under high glucose
concentration and accumulate with age in OA cartilage modifying its
mechanical properties, including stiffness and resistance. An associa-
tion between the levels of AGEs and degradation of cartilage has been
observed [48], although this ﬁnding is not universal [49]. AGEs can
also induce a pro-inﬂammatory and pro-catabolic phenotype of chon-
drocytes via RAGE (receptor of AGE) and toll-like receptors (Fig. 1).
Activation of these receptors decreases peroxisome proliferator-acti-
vated receptor gamma (PPAR-g), which induces oxidative stress
(mitochondrial reactive oxygen species and nitric oxide) and cytokine
release by chondrocytes [50]. High glucose rate increases MMP
expression and oxidative stress in chondrocytes and also elevates the
effect of IL-1b on cytokine release.
Diabetes and synovium
The effect of hyperglycemia on the synovium is less well under-
stood. High glucose concentration increases pro-angiogenic factor
expression in synovial ﬁbroblasts via oxidative stress [51]. Synovial
angiogenesis is known to induce pro-inﬂammatory cells locally. Dia-
betes induces more synovial inﬂammation in vivo models [52], which
is in line with clinical observations of more synovitis in knee OA in
diabetic than in non-diabetic patients [29]. The synovium from OA
patients with T2DM contained markedly more macrophages and
showed elevated TNFa levels as compared to the synovium from OA
patients without diabetes. Moreover, insulin-dependent phosphory-
lation of insulin receptors and serine/threonine kinase Akt (a key
player in the intracellular cascade of insulin action) was blunted in
cultures of OA ﬁbroblast-like synoviocytes from patients with T2DM,
Fig. 1. Pathologic association of type 2 diabetes mellitus and osteoarthritis: involve-
ment of hyperglycemia in local chondrocyte activation.
AGEs, advanced glycation end-products; IL-1b, interleukin-1 beta; MMP matrix
metalloproteinase; mROS, mitochondrial reactive oxygen species; NO, nitric oxide;
PPAR-g, peroxisome proliferator-activated receptor gamma; RAGE, receptor of AGE;
TLR4, toll-like receptor 4.
Reprinted from Diabetes Research and Clinical Practice, 122, Courties A, Sellam J.
Osteoarthritis and type 2 diabetes mellitus: What are the links? 198206, Copyright
(2016), with permission from Elsevier.
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T2DM patients with OA [44].
Diabetes and subchondral bone
Diabetes is known to decrease bone remodeling; high fasting glu-
cose concentration is associated with bone marrow lesions in the
knee joint, which are known to predict OA structural damage [53].
The loss of subchondral bone in diabetic advanced knee OA is identi-
ﬁed by a lower bone mineral density and a higher porosity, indepen-
dent of weight [54]. AGE accumulate in subchondral bone of diabetic
patients more than in non-diabetic patients, which may impact the
mechanical resistance of subchondral bone and display pro-inﬂam-
matory effects [55].
Diabetes and microvascular changes
It is widely known that diabetes can lead to microvascular
changes that increase the risk of some osteoarticular conditions, such
as inﬂammatory peri-arthritis of the shoulder [56], Dupuytren's con-
tracture [57], shoulder hand syndrome of upper extremities and
Charcot joints [58], often involving the lower extremities (e.g. ankle,
disappearing bones of the foot) [58].
The same mechanism (i.e. the presence of microvascular changes)
seems to contribute to the association between diabetes and OA. Sub-
chondral bone has multiple arterial inlets and venous outlets. In the
case of long bones (such as hip), four arterial inputs, the nutrient
artery, periosteal arteries, metaphyseal arteries and epiphyseal arter-
ies are present [59]. In particular, subchondral areas of long bones are
highly vascularized, suggesting high nutrient requirements [60].
Since diabetes is able to lead to relevant microvascular changes it
is likely that diabetes can increase the risk of OA also through
this pathway.
Role of physical exercise in the prevention and management of
T2DM
Lifestyle measures, such as physical activity and body weight con-
trol, are increasingly recognized as important approaches for the pre-
vention and treatment of non-communicable diseases [61]. However,while physical exercise is recognized as an important component of
the management of OA [62], the presence of lower limb OA (hip or
knee) can restrict the possibility to perform physical exercise. Both
optimal nutrition and physical activity can form part of a healthy life-
style for people with T2DM and may play a role in the prevention of
T2DM. The American Diabetes Association (ADA) recognizes lifestyle
management as a fundamental aspect of diabetes care, which
includes diabetes self-management, education and support, medical
nutrition, and physical activity [63]. The ADA recommends that most
adults with T2DM should engage in 150min or more of moderate-to
vigorous intensity aerobic activity per week, along with resistance
exercise of 23 sessions/week, and ﬂexibility training and balance
training 23 times/week for older adults with T2DM.
However, concerns over a lack of physical activity in the general
population has led to a call to action for making physical activity
assessment and prescription a medical standard of care in daily prac-
tice in the US [64]. While there is no strong evidence that diet alone
or physical activity alone can inﬂuence the risk of T2DM, the combi-
nation of diet plus physical activity reduces or delays the incidence of
T2DM in people with impaired glucose tolerance (‘pre-diabetic’ peo-
ple) [65,66].
Intervention programs that include physical activity may halve
the risk of developing T2DM among people at high-risk [6769], and
the reduction in incidence can persist for 10 years following the initial
intervention [70]. There are several biologically-plausible mecha-
nisms by which physical activity may be linked to a lower risk of
T2DM, including weight loss, improved insulin sensitivity, improved
endothelial function, and improved autonomic nervous system func-
tion [71]. Exercise has a positive effect on systemic glucose homeosta-
sis and, in T2DM, exercise does not decrease insulin secretion [72].
Physical activity and exercise are known to have a beneﬁcial effect on
a variety of factors relevant to diabetes and cardiovascular disease,
including blood pressure, lipid proﬁles, and body composition [73]. A
signiﬁcant reduction in both cardiovascular and all-cause mortality
has been shown in long-term follow-up of a lifestyle intervention
among people with impaired glucose intolerance [74].
Safety of anti-osteoarthritis medicines in diabetic patients
Paracetamol
Paracetamol is widely used as ﬁrst-line rescue analgesia in OA,
even though the beneﬁt of paracetamol on pain, physical function
and stiffness is minimal [62,75,76]. Moreover, increasing evidence of
gastrointestinal, cardiovascular, hepatic and renal adverse events
with paracetamol raise questions over its routine, chronic use, espe-
cially at the upper end of standard analgesic doses [20].
Reports of non-overdose paracetamol-associated acute liver fail-
ure leading to transplantation, and staggered paracetamol overdoses
leading to paracetamol-induced hepatotoxicity are a cause of concern
with widespread, unrestricted paracetamol use [77,78]. People taking
paracetamol are nearly 4-times more likely to have abnormal liver
function tests [79]. Non-alcoholic fatty liver disease (NAFLD) and the
more severe form steatohepatitis (NASH) occur frequently in around
5070% of patients with T2DM [80,81]. They affect both those with
elevated aminotransferases and those with normal levels [82]. Obe-
sity and T2DM are also often associated with NAFLD and both obesity
and NAFLD are able to increase the risk and severity of hepatotoxicity
of different drugs, including paracetamol [83,84]. Although there is
limited evidence as yet [85], because paracetamol hepatotoxicity and
liver alterations in NAFLD/NASH-associated liver alterations share
some commonmechanisms, potentiation of harm cannot be excluded
[86]. Furthermore, data suggest that paracetamol toxicity is increased
in diabetic animal models [87]; conversely, metformin may provide
some protection against paracetamol hepatotoxicity [88,89]. Never-
theless, in the absence of further clinical data, caution should be
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for the management of OA-related pain in patients with T2DM and
advanced NAFLD/NASH.
While it is currently viewed that paracetamol can be administered
to patients with liver impairment, as the prevalence of lifestyle-
related liver diseases such as NAFLD is likely to increase, studies to
further the understanding of changes to paracetamol metabolism,
efﬁcacy and toxicity will be invaluable [90]. A small study reported
that people with T2DM eliminate paracetamol with more difﬁculty
than healthy controls [91]. Indeed, further studies are warranted to
answer these research questions: Is the risk of liver toxicity with
paracetamol increased in the diabetic population? And, can paraceta-
mol be prescribed in patients with T2DM and NAFLD/NASH?
Non-steroidal anti-inﬂammatory drugs (NSAIDs)
NSAIDs and renal risk
NSAIDs are widely used and have been linked to acute kidney
injury (AKI), chronic kidney disease, and cardiovascular disease [21].
T2DM causes renal failure, and T2DM and hypertension have become
the most common causes of end-stage renal disease responsible for
more than 50% of cases [92]. NSAID use is associated with an
increased risk of hospitalization in high-risk populations; for exam-
ple, for every 10,000 people treated for 30 days with NSAIDs, there
were 20 extra hospitalizations in the diabetes population (incidence
rate ratio [IRR] 1.31; 95% CI 1.08, 1.60), compared with those not
treated with NSAIDs [93,94].
NSAID users have a 3-fold greater risk for developing a ﬁrst-ever
diagnosis of AKI compared with non-NSAID users in the general pop-
ulation [95]. Hypertension (83%), arthritis (71%), heart failure (44%),
CKD (36%) and diabetes (35%) are prevalent among NSAID users [21].
Although antihypertensive drugs have cardiovascular beneﬁts, vigi-
lance may be warranted when they are used concurrently with
NSAIDs. Moreover, AKI caused by drug-drug interactions between
NSAIDs and angiotensin-converting enzyme inhibitors (ACEIs), angio-
tensin receptor blockers (ARBs), or diuretics is a frequently reported
adverse drug reaction, of which around one-quarter of cases is serious
AKI [96]. The use of selected cardiovascular drugs is associated with a
5-fold increase in risk for AKI. Diuretics present the greatest risk, and
the risk increases with concomitant use of NSAIDs and diuretics (rela-
tive risk [RR] = 11.6; 95% CI 4.2, 32.2) and NSAIDs and calcium channel
blockers (RR = 7.8; 95% CI 3.0, 20.5) [95]. AKI risk is highest among
users of loop diuretic/aldosterone antagonist combinations, in those
over 75 years of age, and in those with renal impairment [97,98].
NSAID use among survivors of an AKI event is common, with
around 68% of survivors found taking NSAIDs both before and after
the AKI event. A history of arthritis (OR: 3.00; 95% CI: 1.92, 4.68) and
paracetamol use (OR: 2.43; 95% CI: 1.50, 3.93) is signiﬁcantly associ-
ated with NSAID use, while prevalent CKD (OR: 0.63; 95% CI: 0.41,
0.98) and diabetes (OR: 0.44; 95% CI: 0.29, 0.69) are not [21].
Antidiabetic agents are frequently associated with diuretics
(»2535%) and blockers of the renin-angiotensin system (ACEI/ARB)
(»5080%) [99]. SGLT2 inhibitors (dapagliﬂozin, canagliﬂozin, empa-
gliﬂozin and ipragliﬂozin) represent a novel approach for the man-
agement of T2DM promoting glucosuria, osmotic diuresis and
natriuresis [100]. SGLT2 inhibitors are generally well-tolerated, even
if some severe adverse events have also been reported [101]. Caution
is particularly recommended in the elderly population, even more
treated with (loop-)diuretics, because of a higher risk of orthostatic
hypotension and dehydration, which may lead to renal impairment.
Indeed, despite encouraging renal safety outcomes reported in clini-
cal cardiovascular outcome trials, scattered reports suggested that
there might be a risk for AKI [102]. As recently discussed, a major
decline in kidney function occasionally occurs, often associated with
an acute illness or with speciﬁc co-administered medications, includ-
ing NSAIDs [102]. Thus, the safety of SGLT2 inhibitors in combinationwith NSAIDs certainly deserves further speciﬁc investigation. So far,
the avoidance of NSAIDs in patients on SGLT2 inhibitors is recom-
mended [22].
NSAIDs and cardiovascular risk
The burden of cardiovascular disease among patients with T2DM
is substantial; around one third to a half of all adults with T2DM has
coronary heart disease, which is the leading cause of early death in
patients with T2DM. T2DM is an independent risk factor for all mani-
festations of coronary heart disease, particularly heart failure, angina
pectoris, re-infarction disability and sudden cardiac death for which
rates among patients with T2DM are at least twice that observed in
non-diabetic patients [103].
All non-selective NSAIDs and COX-2 inhibitors alike have the
potential for gastrointestinal and cardiovascular (CV) toxicity
[23,104,105]. Drug choice within the available NSAIDs class has
therefore been dictated by safety proﬁle, according to different risk
factors and patient's concomitant diseases and medical conditions
[62]. While it was previously thought that selectivity of the NSAID for
the COX-2 enzyme governed the CV toxicity proﬁle, recent results
suggest that CV risk may be drug speciﬁc; rofecoxib is the only NSAID
associated with an increased risk of CV events compared to all other
NSAIDs (OR = 1.61; 95% CI 1.31, 1.98) [106], although etoricoxib may
have a greater risk than celecoxib, while celecoxib poses a similar risk
to naproxen and a reduced risk of major CV event compared with ibu-
profen in OA patients (HR = 0.84; 95% CI 0.72, 0.99) [107,108]. In
patients with T2DM, hypertension, and OA, at equally effective doses
for OA management, treatment with rofecoxib but not celecoxib or
naproxen induced a signiﬁcant increase in 24-h systolic blood pres-
sure [109].
In a recent study using Danish population-based health registries,
the cardiovascular risk of diclofenac initiation was compared with ini-
tiation of other traditional NSAIDs, paracetamol, and no initiation. The
event rate of major adverse cardiovascular events within 30 days of
initiation among diclofenac users increased by 50% compared with
non-initiators (IRR = 1.5; 95% CI 1.4, 1.7), 20% compared with paracet-
amol or ibuprofen initiators (both IRR = 1.2; 95% CI 1.1, 1.3), and 30%
compared with naproxen initiators (IRR 1.3; 95% CI 1.1, 1.5). Although
the relative risk of major adverse cardiovascular events was highest
in individuals with low or moderate baseline risk (i.e., diabetes melli-
tus), the absolute risk was highest in individuals with high baseline
risk (i.e., previous myocardial infarction or heart failure) [110]. In a
study of diabetes patients treated in primary care in Saudi Arabia
(N = 443; March 2016), inappropriate prescribing of NSAIDs was
found in 66% of patients at high cardiovascular risk, contravening cur-
rent clinical guidelines and recommendations of regulatory agencies
[111].
Topical NSAIDs
For OA of the hands and knees, topical NSAIDs provide efﬁcacy,
with far less systemic distribution than oral NSAIDs [112,113]. Obser-
vational studies and post-hoc analysis of pooled data from placebo-
controlled trials suggested that long-term topical diclofenac sodium
1% treatment is safe in the subpopulation of patients with an elevated
risk of NSAID-related adverse events, such as the elderly and those
with the comorbidities of T2DM, hypertension, and cardiovascular
disease [114,115].
SYSADOAs
Slow Acting Symptomatic Drugs in Osteoarthritis (SYSADOAs)
include diverse medications possibly able to interfere with disease
pathogenetic processes, inducing a moderate symptomatic effect
with slow onset of action and, in some cases, a joint structure-modi-
fying effect in long-term trials [116121]. They include mainly
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over-the-counter glucosamine sulfate or hydrochloride), chondroitin
sulfate, diacerein and avocado soybean unsaponiﬁables, with differ-
ent levels of evidence for efﬁcacy [122125]. Clinical trials and sys-
tematic reviews outline a very good safety proﬁle of the SYSADOAs
glucosamine and chondroitin sulfate [126129], and some adverse
events with diacerein and avocado soybean unsaponiﬁables
[130,131]. No concern with respect to T2DM or any interaction with
glucose metabolism has been noted in clinical trials or meta-analyses
for chondroitin sulfate, diacerein or avocado soybean unsaponiﬁables.
However, questions have been raised over time on a possible interfer-
ence of glucosamine with glucose metabolism, based on precise
mechanistic hypotheses.
Insulin resistance, a major contributing factor to the pathogenesis
of T2DM, is characterized by reduced rates of insulin-mediated glu-
cose uptake e.g. into skeletal muscle or adipocytes. Hyperglycemia
induces or worsens insulin resistance, and in vitro studies show that
glucose-induced insulin resistance involves impaired recruitment of
intracellular glucose transporters to the cell surface. Glucosamine is a
product of glucose metabolism and, in vitro, was shown to substitute
for glucose and be more potent in promoting glucose transport
desensitization [132]. Actually, in vitro studies showed that high glu-
cosamine concentrations may increase the activity of the hexosamine
pathway, a metabolic process functioning as a nutrient sensor and
modulating insulin sensitivity and glucose uptake [133]. Effects of
glucosamine on insulin resistance via the hexosamine pathway can
be seen in vitro (in rodents), mainly at dramatically high concentra-
tions [134]. Excessive emphasis was given to this pathway for postu-
lated glucosamine toxicity, since it was wrongly believed that this
was also the mechanism of action for the therapeutic effect in OA
(stimulation of proteoglycans synthesis).
However, parenteral administration of glucosamine to humans at
similarly high concentrations in repeated studies failed to show simi-
lar results, indicating species differences in sensitivity, or possible
mechanistic differences i.e. less operational relevance of the hexos-
amine pathway in the regulation of insulin sensitivity in humans
[135,136]. Clinical trials at oral recommended doses for OA treatment
showed no interference with glucose metabolism in normoglycemic
subjects and in most subjects with hyperglycemia, insulin sensitivity
impairment, pre-diabetes or diabetes [137,138]. Additional analyses
of the GUIDE study found that pCGS (1500mg/day) for 6 months
does not modify plasma glucose levels in the overall population, or in
hyperglycemic patients [139,140]. Systematic reviews on the effects
of glucosamine on glucose metabolism in humans ﬁnd that adminis-
tration of glucosamine at usual oral doses in humans or OA patients
in clinical trials is well-tolerated by normal, diabetic, or pre-diabetic
patients [141,142]. However, a minority of clinical studies have indi-
cated non-signiﬁcant trends for interference in some of the latter sub-
jects. A non-signiﬁcant increase in glycated hemoglobin levels was
found in overweight women who received pCGS treatment for
2.5 years in the PROOF trial, and with up to 6.5 years of follow-up
[143,144]. Thus, in accordance with the summary of Product Charac-
teristics for pCGS, it seems reasonable to advise caution at the start of
treatment with glucosamine in diabetic patients, with no speciﬁc rec-
ommendations for other patients [145].
IA corticosteroids
Intra-articular (IA) corticosteroid injections may be used for the
local symptomatic control of joint arthritis due to their anti-inﬂam-
matory properties. However, it has been shown that locally-injected
corticosteroids are absorbed into the systemic circulation [146].
Parentally-administered steroids are known to affect glucose metabo-
lism and can cause abnormal blood glucose levels in patients with
diabetes, which may be a concern when administering IA corticoste-
roid injections.Choudhry et al. recently performed a systematic review to iden-
tify studies that examined the effect of IA corticosteroid injections
on blood glucose levels in patients with diabetes [147]. They identi-
ﬁed 532 citations, however, after inclusion criteria were applied
only 7 studies with a total of 72 patients were included in the meta-
analysis. All studies showed a rise in blood glucose levels following
IA corticosteroid injections, which was described as substantial in
4 studies, reaching a peak as high as 500mg/dL. The timing of the
peak glucose levels may vary from several hours post injection to
1015 days. Consequently, patients with diabetes should monitor
their blood glucose levels following IA corticosteroid injections for
2448 h post-injection for a potential risk of hyperglycemia, and
antihyperglycemic therapies should be adjusted accordingly.
Insulin-treated patients with T2DM commonly require transient up-
titration of insulin doses after IA corticosteroid injections. Patients
with diabetes who are taking insulin should be encouraged to check
their blood glucose levels at a minimum of twice daily after receiv-
ing an intra-articular corticosteroid injection in order to determine
whether they need short-acting insulin.
Hyaluronic acid
Intra-articular hyaluronic acid (IAHA) is a local treatment modality
targeted to avoid the systemic side effects usually observed after IA
corticosteroid injection (of particular difﬁculty in patients with
T2DM), or after oral administration of analgesics and NSAIDs [148]. It
has been reported that the results obtained with IAHA are not signiﬁ-
cantly different from continuous oral NSAID treatment used in the
short and medium term, i.e. providing moderate symptomatic relief
of knee OA pain, function and stiffness [149]. IAHA was superior to IA
corticosteroids from 8 to 26 weeks post-treatment regarding knee
pain [150]. IAHA is a safe alternative to oral NSAIDs and opioids for
OA; a systematic review and meta-analysis of the safety of 18 HA
products involving over 13,000 patients found a very low incidence
of adverse events, most commonly transient local reactions that sub-
sided rapidly [151].
IAHA injections have demonstrated clinical beneﬁt in knee OA and
seem to offer a good beneﬁt-risk balance among the pharmacologic
options [152,153]. Based on the available evidence and guidelines,
the European Society for Clinical and Economic Aspects of Osteoporo-
sis, Osteoarthritis andMusculoskeletal Diseases (ESCEO) recommends
using IAHA in patients with knee OA remaining symptomatic despite
continuous or intermittent treatment with conventional pharmaco-
logic treatment modalities, i.e., paracetamol, SYSADOAs and NSAIDs,
as well as in patients with co-morbidities precluding the use of
NSAIDs or IA corticosteroids, such as diabetic patients [148,154,155].
No interaction of IAHA use in OA with glucose metabolism or associa-
tion with hyperglycemia has been reported in the current literature
to date, even in patients who received repeated HA cycles over sev-
eral years among whom diabetes was a common comorbidity (16% of
patients) [156]. HA appears to be safe in diabetic patients and a meta-
analysis reported that HA is beneﬁcial in treating diabetic foot by
increasing the rate of wound healing [157] suggesting a potential
(albeit peculiar) role of HA in treating OA in diabetic people.
Bariatric surgery
Obesity is a well-known risk factor for both T2DM [5] and OA
[158,159]. Obesity accelerates the development of OA of the knee and
hip by exerting deleterious effects on joints through both biomechan-
ical and also systemic inﬂammatory changes [159]. Bariatric/meta-
bolic surgery has proven to be the most successful procedure to
improve glucose control and sustained diabetes remission has been
reported in many patients. The success is explained not only by the
remarkable and sustained weight reduction, but also by several endo-
crine and metabolic improvements [160]. Besides the correction of
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nents of MetS, hypertension, atherogenic dyslipidemia and insulin
resistance, leading to better CV outcomes [161]. In addition, several
studies reported a reduction in low-grade inﬂammation and various
inﬂammatory markers [162164].
The inﬂammatory pathway reduction following weight loss obtained
through bariatric surgery is connected both with the improvement of
some rheumatic diseases and a reduction in medication use (steroids
and NSAIDs) [165]. Bariatric surgery with subsequent marked weight
loss is likely to improve knee pain, joint function and stiffness in (mor-
bidly) obese and obese adult patients with T2DM. However, with the cur-
rent available evidence, there is further need for high-quality studies
[159,166]. Among a cohort of participants with severe obesity undergo-
ing bariatric surgery, a large percentage experienced improvement, com-
pared with baseline, in pain, physical function, and walk time over
3 years, but the percentage with improvement in pain and joint function
decreased between year 1 and year 3 [167].
According to a systematic review and meta-analysis, for most peri-
operative outcomes, bariatric surgery prior to total hip or total knee
arthroplasty does not signiﬁcantly reduce the complication rates or
improve the clinical outcome [168]. However, decreased operative time
and length of hospital stay were observed among patients who under-
went total hip or knee arthroplasty after versus before their bariatric sur-
gery [169]. Optimal timing of orthopedic and bariatric surgery has yet to
be established. There are also ﬁnancial and ethical implications of use of
bariatric surgery for risk reduction before total joint arthroplasty [170].
Fundamental clinical questions remain regarding the optimal manage-
ment of obesity with T2DM and lower extremity OA, which should be
the focus of future collaborations across disciplines providing care to
patients with both conditions [159].
Discussion
While T2DM and OA are known to frequently coincide (along with
obesity/overweight, and frequently in the context of MetS), whether
any causal relationship between the two disorders exists is a question
of research interest. Analysis of studies involving more than 1 million
participants shows a clear association of T2DM and OA, and an ele-
vated risk of OA is demonstrated in patients with T2DM even when
controlled for body weight.
Studies ﬁnding an association between T2DM and hand OA raise
the question of whether DM impacts on the pathophysiology of OA
beyond that which may easily be explained, e.g. the mechanical
impact of overweight/obesity (which often accompanies T2DM) on
lower limb OA. An association between pain in erosive hand OA and
diabetes (in type 2 but also in type 1, may be linked to low grade
inﬂammation related to MetS) requires further investigation.
Evidence supports a role for T2DM on OA pathogenesis through
two major pathways: oxidative stress resulting from chronic hyper-
glycemia and leading to overproduction of pro-inﬂammatory cyto-
kines and AGEs in joint tissue; and insulin resistance which may
impact both locally and through systemic low-grade chronic inﬂam-
mation. Dysglycemia, including T2DM, is only one factor of MetS, and
whether other components of MetS including high blood pressure
and atherogenic dyslipidemia together or independently impact on
OA pathophysiology remains to be explored.
The impact of T2DM on OA outcomes is also of research interest.
The presence of T2DM is associated with OA progression, severe clini-
cal symptoms, and joint structural changes, while treatment of T2DM
may reduce the progression of knee OA. T2DM is shown to have a
negative impact on arthroplasty, including decreased functional out-
comes and greater need for revision arthroplasty.
Future research is needed to understand if diabetes control and
prevention can modulate OA occurrence and progression in humans.
Interventions involving physical activity and body weight control are
known to have positive outcomes in the prevention and treatment ofT2DM. Concerns over a lack of physical activity in the US population
have led to a call to action for making physical activity prescription a
medical standard of care [64]. Recommendations for management of
OA also include a core set of treatment modalities including weight
management and exercise programs [62].
In this review, we have sought to explore whether the co-pres-
ence of T2DM poses any additional safety issues for the pharmaco-
logic treatment of OA. Due to the fragility of patients with diabetes,
the recommendation to prioritize drugs for which the beneﬁts are
not outweighed by harms is of critical importance. Evidence is
mounting for safety concerns with some of the most frequently pre-
scribed anti-OA medications, including paracetamol and NSAIDs.
Paracetamol is associated with some degree of liver toxicity. Liver dis-
ease (NAFLD) occurs frequently in people with T2DM, and whether
paracetamol can be prescribed safely in OA patients with co-morbid
T2DM and NAFLD remains to be determined. NSAIDs are linked to
renal impairment, and drug-drug interactions between NSAIDs and
other drug classes, e.g. anti-hypertensive agents, resulting in renal
injury have been reported. The antidiabetic agent class of SGLT2
inhibitors has potential to impact on renal function, especially when
conditions leading to dehydration are present; thus, the co-adminis-
tration of NSAIDs and SGLT2 inhibitors is not recommended.
NSAIDs increase the risk of cardiovascular disease in the general
population, and although there is little direct evidence for elevated
cardiovascular risk with NSAIDs in people with diabetes, as T2DM is a
prominent risk factor for cardiovascular disease we may speculate on
a higher risk in patients with T2DM. The same may be true for the
renal risk of NSAIDs.
A concern raised over potential interference of the SYSADOA glu-
cosamine on glucose metabolism is not borne out by the majority of
the clinical evidence. There is limited evidence for a non-signiﬁcant
increase in glycated hemoglobin levels in overweight women pre-
scribed glucosamine for OA prevention. While in systematic reviews,
glucosamine administered to OA patients at usual oral doses is well-
tolerated by both diabetic and pre-diabetic patients.
IA corticosteroid injections are associated with a rise in blood glucose
levels and hence an elevated risk of hyperglycemia in OA patients with
T2DM; thus, monitoring of blood glucose levels following IA corticoste-
roid injections is recommended for 2448 h post-injection with cortico-
steroids and antihyperglycemic therapy may be transiently intensiﬁed if
necessary. Alternatively, IAHA may be used in knee OA patients remain-
ing symptomatic following treatment with paracetamol, SYSADOAs and
NSAIDs, as well as in patients with co-morbidities precluding the use of
NSAIDs or IA corticosteroids, such as diabetic patients. HA appears to be
safe in diabetic patients and may have a potential role promoting wound
healing in diabetic foot ulceration.
In conclusion, the selection of therapy to treat OA symptoms in
patients with co-morbid T2DM may require careful consideration of
the evidence base to avoid untoward safety issues. Further research is
needed to better identify any safety concerns for treatment of OA
patients with T2DM, and to optimize long-term patient management.
Authors’ statement
The views expressed in this article represent the outcomes of aWork-
ing Group jointly organized by the European Society for Clinical and Eco-
nomic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal
Diseases (ESCEO) and the World Health Organization Collaborating Cen-
ter for Public Health Aspects of Musculoskeletal Health and Aging, Liege,
Belgium, and held in Zurich, Switzerland, on January 17th, 2018.
The expert group comprised a global representation of clinicians,
endocrinologists, surgeons, researchers, clinical pharmacologists, epi-
demiologists, geriatricians, and members of regulatory agencies. They
were invited for their expertise and knowledge regarding osteoar-
thritis and diabetes mellitus. Agreement on the principles outlined in
this article were based on an exchange of peer-reviewed publications
16 N. Veronese et al. / Seminars in Arthritis and Rheumatism 49 (2019) 919prior to the meeting and a one-day interactive meeting. All authors
meet the ICMJE criteria for authorship for this manuscript, take
responsibility for the integrity of the work as a whole, and have given
ﬁnal approval to the version to be published.Role of the funding source
The meeting was funded by the ESCEO, a Belgian not-for-proﬁt
organization.
The authors thank the Chair for Biomarkers of Chronic Diseases
and the International Scientiﬁc Partnership Program (ISPP#0111) at
King Saud University, Riyadh, Saudi Arabia for their support.Role of medical writer/editor
Editorial assistance in the preparation of this manuscript was pro-
vided by Lisa Buttle, Ph.D., of Medscript Ltd., which was funded by
the ESCEO asbl, Belgium.Declaration of interests
O. Bruyere reports grants from Biophytis, IBSA, MEDA, Servier,
SMB, and Theramex, outside of the submitted work.
C. Cooper reports personal fees from Alliance for Better Bone
Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pﬁzer,
Roche, Servier, Takeda and UCB, outside of the submitted work.
R. Rizzoli reports personal fees for lecture or advisory boards from
Radius Health, Labatec, Nestle and Danone, outside of the submitted
work.
A. J. Scheen declares no conﬂict of interest with the content of this
paper. He has received lecturer/scientiﬁc advisor/clinical investigator
fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck
Sharp & Dohme, Novartis, NovoNordisk, Sanoﬁ and Servier.
J. Branco declares no conﬂict of interest with the content of this
paper. He has received scientiﬁc advisor and/or speaker and/or clini-
cal investigator fees from AstraZeneca, BIAL, Biogen, Eli Lilly, Novartis
and Pﬁzer.
L.C. Rovati is a former employee of Rottapharm, the company that
developed and commercialized prescription crystalline glucosamine
sulfate, now commercialized by Mylan. He is currently Chief Scientiﬁc
Ofﬁcer of Rottapharm Biotech, which has no commercial interests in
glucosamine or any other drugs for OA discussed here.
E. Dennison reports personal fees for lectures or advisory boards
from UCB and Pﬁzer, outside of the submitted work.
J.F. Kaux reports a grant from Eli Lilly, outside of the submitted
work.
E. Maheu reports personal fees from Expanscience, FIDIA, IBSA -
GENEVRIER, LCA (France), TRB Chemedica, Rottapharm - Meda, out-
side of the submitted work.
N. Al-Daghri, J-Y. Reginster, G. Herrero-Beaumont, D. Uebelhart, N.
Veronese, M. Hochberg, R. Roth, R. Chapurlat, and M. Vlaskovska
report nothing to disclose.References
[1] Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global
estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res
Clin Pract 2014;103(2):137–49. https://doi.org/10.1016/j.diabres.2013.11.002.
[2] Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived
with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010:
a systematic analysis for the Global Burden of Disease Study 2010. Lancet
2012;380(9859):2163–96. https://doi.org/10.1016/s0140-6736(12)61729-2.
[3] Visser AW, de Mutsert R, le Cessie S, den Heijer M, Rosendaal FR, Kloppenburg M,
et al. The relative contribution of mechanical stress and systemic processes in dif-
ferent types of osteoarthritis: the NEO study. Ann Rheum Dis 2015;74(10):1842–7.
https://doi.org/10.1136/annrheumdis-2013-205012.[4] Teodoro JS, Varela AT, Rolo AP, Palmeira CM. High-fat and obesogenic diets: cur-
rent and future strategies to ﬁght obesity and diabetes. Genes Nutr 2014;9
(4):406. https://doi.org/10.1007/s12263-014-0406-6.
[5] Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of
common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol
2014;2(11):911–22. https://doi.org/10.1016/S2213-8587(14)70004-X.
[6] CDC. Centers for disease control and prevention: national diabetes statistics
report. Atlanta: GA Centers for Disease Control and Prevention, U.S. Department
of Health and Human Services; 2017.
[7] Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates
of the prevalence of arthritis and other rheumatic conditions in the United States.
Part II. Arthritis Rheum 2008;58(1):26–35. https://doi.org/10.1002/art.23176.
[8] Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new
paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58
(4):773–95. https://doi.org/10.2337/db09-9028.
[9] Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: pathogenesis and
treatment. Lancet 2008;371(9631):2153–6. https://doi.org/10.1016/S0140-6736
(08)60932-0.
[10] King KB, Rosenthal AK. The adverse effects of diabetes on osteoarthritis: update
on clinical evidence and molecular mechanisms. Osteoarthr Cartil 2015;23
(6):841–50. https://doi.org/10.1016/j.joca.2015.03.031.
[11] CDC. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limi-
tation United States, 2010-2012. MorbMortal Wkly Rep 2013;62(44):869–73.
[12] Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance
for clinical practice. Lancet 2011;377(9783):2115–26. https://doi.org/10.1016/
S0140-6736(11)60243-2.
[13] Yusuf E, Nelissen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, van Osch
G, et al. Association between weight or body mass index and hand osteoarthri-
tis: a systematic review. Ann Rheum Dis 2010;69(4):761–5. https://doi.org/
10.1136/ard.2008.106930.
[14] Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus
and osteoarthritis: systematic literature review and meta-analysis. RMD Open
2015;1(1):e000077. https://doi.org/10.1136/rmdopen-2015-000077.
[15] Alberti KG, Zimmet P, Shaw J. Group IDFETFC. The metabolic syndromea new
worldwide deﬁnition. Lancet 2005;366(9491):1059–62. https://doi.org/
10.1016/S0140-6736(05)67402-8.
[16] Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in indi-
viduals with osteoarthritis: an analysis of NHANES III data. Postgrad Med
2009;121(6):9–20. https://doi.org/10.3810/pgm.2009.11.2073.
[17] Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. Nat
Rev Rheumatol 2012;8(12):729–37. https://doi.org/10.1038/nrrheum.2012.135.
[18] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Har-
monizing the metabolic syndrome: a joint interim statement of the Interna-
tional Diabetes Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and International Asso-
ciation for the Study of Obesity. Circulation 2009;120(16):1640–5. https://doi.
org/10.1161/CIRCULATIONAHA.109.192644.
[19] Yasuda E, Nakamura R, Matsugi R, Goto S, Ikenaga Y, Kuroda K, et al. Association
between the severity of symptomatic knee osteoarthritis and cumulative meta-
bolic factors. Aging Clin Exp Res 2018;30(5):481–8. https://doi.org/10.1007/
s40520-017-0808-6.
[20] Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al.
Paracetamol: not as safe as we thought? A systematic literature review of obser-
vational studies. Ann Rheum Dis 2016;75(3):552–9. https://doi.org/10.1136/
annrheumdis-2014-206914.
[21] Lipworth L, Abdel-Kader K, Morse J, Stewart TG, Kabagambe EK, Parr SK, et al.
High prevalence of non-steroidal anti-inﬂammatory drug use among acute kid-
ney injury survivors in the southern community cohort study. BMC Nephrol
2016;17(1):189. https://doi.org/10.1186/s12882-016-0411-7.
[22] Heyman SN, Khamaisi M, Rosen S, Rosenberger C, Abassi Z. Potential hypoxic
renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding
concomitant use of nsaids and iodinated contrast media. Diabetes Care 2017;40
(4):e40–e1. https://doi.org/10.2337/dc16-2200.
[23] Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and
upper gastrointestinal effects of non-steroidal anti-inﬂammatory drugs: meta-
analyses of individual participant data from randomised trials. Lancet 2013;382
(9894):769–79. https://doi.org/10.1016/s0140-6736(13)60900-9.
[24] Nielen JT, Emans PJ, Dagnelie PC, Boonen A, Lalmohamed A, de Boer A, et al.
Severity of diabetes mellitus and total hip or knee replacement: a population-
based case-control study. Medicine 2016;95(20):e3739. https://doi.org/
10.1097/MD.0000000000003739.
[25] Dahaghin S, Bierma-Zeinstra SM, Koes BW, Hazes JM, Pols HA. Do metabolic factors
add to the effect of overweight on hand osteoarthritis? The Rotterdam study. Ann
RheumDis 2007;66(7):916–20. https://doi.org/10.1136/ard.2005.045724.
[26] Magnusson K, Hagen KB, Osteras N, Nordsletten L, Natvig B, Haugen IK. Diabetes
is associated with increased hand pain in erosive hand osteoarthritis: data from
a population-based study. Arthritis Care Res 2015;67(2):187–95. https://doi.
org/10.1002/acr.22460.
[27] Frey N, Hugle T, Jick SS, Meier CR, Spoendlin J. Type II diabetes mellitus and inci-
dent osteoarthritis of the hand: a population-based case-control analysis. Osteo-
arthr Cartil 2016;24(9):1535–40. https://doi.org/10.1016/j.joca.2016.04.005.
[28] Eymard F, Parsons C, Edwards MH, Petit-Dop F, Reginster JY, Bruyere O, et al.
Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthr Cartil
2015;23(6):851–9. https://doi.org/10.1016/j.joca.2015.01.013.
N. Veronese et al. / Seminars in Arthritis and Rheumatism 49 (2019) 919 17[29] Schett G, Kleyer A, Perricone C, Sahinbegovic E, Iagnocco A, Zwerina J, et al. Dia-
betes is an independent predictor for severe osteoarthritis: results from a longi-
tudinal cohort study. Diabetes Care 2013;36(2):403–9. https://doi.org/10.2337/
dc12-0924.
[30] Shirinsky IV, Shirinsky VS. Effects of medication-treated diabetes on incidence
and progression of knee osteoarthritis: a longitudinal analysis of the osteoarthri-
tis initiative data. Rheumatol Int 2017;37(6):983–91. https://doi.org/10.1007/
s00296-017-3676-7.
[31] Barnett LA, Jordan KP, Edwards JJ, van der Windt DA. Does metformin protect
against osteoarthritis? An electronic health record cohort study. Prim Health
Care Res Dev 2017;18(6):623–8. https://doi.org/10.1017/S1463423617000287.
[32] Lu CH, Chung CH, Lee CH, Hsieh CH, Hung YJ, Lin FH, et al. Combination COX-2
inhibitor and metformin attenuate rate of joint replacement in osteoarthritis
with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan.
PLoS One 2018;13(1):e0191242. https://doi.org/10.1371/journal.pone.0191242.
[33] Scheen AJ, Esser N, Paquot N. Antidiabetic agents: potential anti-inﬂammatory
activity beyond glucose control. Diabetes Metab 2015;41(3):183–94. https://doi.
org/10.1016/j.diabet.2015.02.003.
[34] Nielen JT, de Vries F, Dagnelie PC, van den Bemt BJ, Emans PJ, Lalmohamed A,
et al. Use of thiazolidinediones and the risk of elective hip or knee replacement:
a population based case-control study. Br J Clin Pharmacol 2016;81(2):370–8.
https://doi.org/10.1111/bcp.12786.
[35] Courties A, Sellam J. Osteoarthritis and type 2 diabetes mellitus: what are the
links? Diabetes Res Clin Pract 2016;122:198–206. https://doi.org/10.1016/j.dia-
bres.2016.10.021.
[36] Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint
inﬂammation and osteoarthritis. Osteoarthr Cartil 2015;23(11):1955–65.
https://doi.org/10.1016/j.joca.2015.05.016.
[37] Wang Y, Wluka AE, Hodge AM, English DR, Giles GG, O'Sullivan R, et al. Effect of
fatty acids on bonemarrow lesions and knee cartilage in healthy, middle-aged sub-
jects without clinical knee osteoarthritis. Osteoarthr Cartil 2008;16(5):579–83.
https://doi.org/10.1016/j.joca.2007.09.007.
[38] Askari A, Ehrampoush E, Homayounfar R, Bahramali E, Farjam M. Serum insulin
in pathogenesis and treatment of osteoarthritis. Med Hypotheses 2017;99:45–6.
https://doi.org/10.1016/j.mehy.2016.12.010.
[39] Al-Jarallah K, Shehab D, Abdella N, Al Mohamedy H, Abraham M. Knee osteoar-
thritis in type 2 diabetes mellitus: does insulin therapy retard osteophyte forma-
tion? Med Princ Pract 2016;25(1):12–7. https://doi.org/10.1159/000441418.
[40] Rosa SC, Ruﬁno AT, Judas F, Tenreiro C, Lopes MC, Mendes AF. Expression and
function of the insulin receptor in normal and osteoarthritic human chondro-
cytes: modulation of anabolic gene expression, glucose transport and GLUT-1
content by insulin. Osteoarthr Cartil 2011;19(6):719–27. https://doi.org/
10.1016/j.joca.2011.02.004.
[41] Ribeiro M, Lopez de Figueroa P, Blanco FJ, Mendes AF, Carames B. Insulin
decreases autophagy and leads to cartilage degradation. Osteoarthr Cartil
2016;24(4):731–9. https://doi.org/10.1016/j.joca.2015.10.017.
[42] Gregor MF, Hotamisligil GS. Inﬂammatory mechanisms in obesity. Annu Rev
Immunol 2011;29:415–45. https://doi.org/10.1146/annurev-immunol-031210-
101322.
[43] Grifﬁn TM, Huffman KM. Editorial: insulin resistance: releasing the brakes on
synovial inﬂammation and osteoarthritis? Arthritis Rheumatol 2016;68
(6):1330–3. https://doi.org/10.1002/art.39586.
[44] Hamada D, Maynard R, Schott E, Drinkwater CJ, Ketz JP, Kates SL, et al. Suppres-
sive effects of insulin on tumor necrosis factor-dependent early osteoarthritic
changes associated with obesity and type 2 diabetes mellitus. Arthritis Rheuma-
tol 2016;68(6):1392–402. https://doi.org/10.1002/art.39561.
[45] Courties A, Sellam J, Berenbaum F. Metabolic syndrome-associated osteoarthri-
tis. Curr Opin Rheumatol 2017;29(2):214–22. https://doi.org/10.1097/BOR.000
0000000000373.
[46] Mobasheri A, Neama G, Bell S, Richardson S, Carter SD. Human articular chondro-
cytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and
GLUT9. Cell Biol Int 2002;26(3):297–300. https://doi.org/10.1006/cbir.2001.0850.
[47] Rosa SC, Goncalves J, Judas F, Mobasheri A, Lopes C, Mendes AF. Impaired glu-
cose transporter-1 degradation and increased glucose transport and oxidative
stress in response to high glucose in chondrocytes from osteoarthritic versus
normal human cartilage. Arthritis Res Ther 2009;11(3):R80. https://doi.org/
10.1186/ar2713.
[48] Eaton CB, Sayeed M, Ameernaz S, Roberts MB, Maynard JD, Driban JB, et al. Sex
differences in the association of skin advanced glycation endproducts with knee
osteoarthritis progression. Arthritis Res Ther 2017;19(1):36. https://doi.org/
10.1186/s13075-017-1226-z.
[49] Vos PA, Welsing PM, deGroot J, Huisman AM, Oostveen JC, Reijman M, et al. Skin
pentosidine in very early hip/knee osteoarthritis (CHECK) is not a strong inde-
pendent predictor of radiographic progression over 5 years follow-up. Osteo-
arthr Cartil 2013;21(6):823–30. https://doi.org/10.1016/j.joca.2013.03.006.
[50] Chen YJ, Sheu ML, Tsai KS, Yang RS, Liu SH. Advanced glycation end products
induce peroxisome proliferator-activated receptor gamma down-regulation-
related inﬂammatory signals in human chondrocytes via toll-like receptor-4
and receptor for advanced glycation end products. PLoS One 2013;8(6):e66611.
https://doi.org/10.1371/journal.pone.0066611.
[51] Tsai CH, Chiang YC, Chen HT, Huang PH, Hsu HC, Tang CH. High glucose induces
vascular endothelial growth factor production in human synovial ﬁbroblasts
through reactive oxygen species generation. Biochim Biophys Acta 2013;1830
(3):2649–58. https://doi.org/10.1016/j.bbagen.2012.12.017.[52] Ribeiro M, Lopez de Figueroa P, Nogueira-Recalde U, Centeno A, Mendes AF,
Blanco FJ, et al. Diabetes-accelerated experimental osteoarthritis is prevented by
autophagy activation. Osteoarthr Cartil 2016;24(12):2116–25. https://doi.org/
10.1016/j.joca.2016.06.019.
[53] Davies-Tuck ML, Wang Y, Wluka AE, Berry PA, Giles GG, English DR, et al.
Increased fasting serum glucose concentration is associated with adverse knee
structural changes in adults with no knee symptoms and diabetes. Maturitas
2012;72(4):373–8. https://doi.org/10.1016/j.maturitas.2012.05.013.
[54] Wen CY, Chen Y, Tang HL, Yan CH, LuWW, Chiu KY. Bone loss at subchondral plate
in knee osteoarthritis patients with hypertension and type 2 diabetes mellitus.
Osteoarthr Cartil 2013;21(11):1716–23. https://doi.org/10.1016/j.joca.2013.06.027.
[55] Franke S, Ruster C, Pester J, Hofmann G, Oelzner P, Wolf G. Advanced glycation
end products affect growth and function of osteoblasts. Clin Exp Rheumatol
2011;29(4):650–60.
[56] Charnley J. Periarthritis of the shoulder. Postgrad Med J 1959;35(405):384.
[57] Kischer CW, Speer DP. Microvascular changes in Dupuytren's contracture.
J Hand Surg 1984;9(1):58–62.
[58] Schramm JC, Dinh T, Veves A. Microvascular changes in the diabetic foot. Int
J Low ExtremWounds 2006;5(3):149–59.
[59] Johnson EO, Soultanis K, Soucacos PN. Vascular anatomy and microcirculation of
skeletal zones vulnerable to osteonecrosis: vascularization of the femoral head.
Orthop Clin 2004;35(3):285–91.
[60] Findlay DM. Vascular pathology and osteoarthritis. Rheumatology 2007;46
(12):1763–8. https://doi.org/10.1093/rheumatology/kem191.
[61] Kushner RF, Sorensen KW. Lifestyle medicine: the future of chronic disease
management. Curr Opin Endocrinol Diabetes Obes 2013;20(5):389–95. https://
doi.org/10.1097/01.med.0000433056.76699.5d.
[62] Bruyere O, Cooper C, Pelletier JP, Branco J, Brandi ML, Guillemin F, et al. An algo-
rithm recommendation for the management of knee osteoarthritis in Europe and
internationally: a report from a task force of the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis
Rheum 2014;44(3):253–63. https://doi.org/10.1016/j.semarthrit.2014.05.014.
[63] ADA. American Diabetes Association. 4. Lifestyle management: standards of
medical care in diabetes 2018. Diabetes Care 2018;41(Suppl. 1):S38–50. https://
doi.org/10.2337/dc18-S004.
[64] Sallis RE, Matuszak JM, Baggish AL, Franklin BA, Chodzko-Zajko W, Fletcher BJ,
et al. Call to action on making physical activity assessment and prescription a
medical standard of care. Curr Sports Med Rep 2016;15(3):207–14. https://doi.
org/10.1249/JSR.0000000000000249.
[65] Hemmingsen B, Gimenez-Perez G, Mauricio D, Roque IFM, Metzendorf MI,
Richter B. Diet, physical activity or both for prevention or delay of type 2 diabe-
tes mellitus and its associated complications in people at increased risk of devel-
oping type 2 diabetes mellitus. Cochrane Database Syst Rev 2017;12:CD003054.
https://doi.org/10.1002/14651858.CD003054.pub4.
[66] Kriska A. Can a physically active lifestyle prevent type 2 diabetes? Exerc Sport
Sci Rev 2003;31(3):132–7.
[67] Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exer-
cise in preventing NIDDM in people with impaired glucose tolerance. The Da
Qing IGT and diabetes study. Diabetes Care 1997;20(4):537–44.
[68] Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P,
et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among sub-
jects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343–50.
https://doi.org/10.1056/NEJM200105033441801.
[69] Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA,
et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or
metformin. N Engl J Med 2002;346(6):393–403. https://doi.org/10.1056/NEJ-
Moa012512.
[70] Diabetes Prevention Program Research GKnowler WC, Fowler SE, Hamman RF,
Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and
weight loss in the diabetes prevention program outcomes study. Lancet
2009;374(9702):1677–86. https://doi.org/10.1016/S0140-6736(09)61457-4.
[71] Carnethon MR, Craft LL. Autonomic regulation of the association between exer-
cise and diabetes. Exerc Sport Sci Rev 2008;36(1):12–8. https://doi.org/10.1097/
jes.0b013e31815e3dc5.
[72] Dela F, Prats C, Helge JW. Exercise interventions to prevent and manage type 2
diabetes: physiological mechanisms. Med Sport Sci 2014;60:36–47. https://doi.
org/10.1159/000357334.
[73] Lumb A. Diabetes and exercise. Clin Med 2014;14(6):673–6. https://doi.org/
10.7861/clinmedicine.14-6-673.
[74] Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality,
all-cause mortality, and diabetes incidence after lifestyle intervention for people
with impaired glucose tolerance in the Da Qing diabetes prevention study: a
23-year follow-up study. Lancet Diabetes Endocrinol 2014;2(6):474–80. https://
doi.org/10.1016/S2213-8587(14)70057-9.
[75] Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetamino-
phen for osteoarthritis. Cochrane Database Syst Rev 2006(1):CD004257. https://
doi.org/10.1002/14651858.CD004257.pub2.
[76] Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al.
OARSI recommendations for the management of hip and knee osteoarthritis:
part III: changes in evidence following systematic cumulative update of research
published through January 2009. Osteoarthr Cartil 2010;18(4):476–99. https://
doi.org/10.1016/j.joca.2010.01.013.
[77] Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, et al.
Liver transplant associated with paracetamol overdose: results from the
18 N. Veronese et al. / Seminars in Arthritis and Rheumatism 49 (2019) 919seven-country SALT study. Br J Clin Pharmacol 2015;80(3):599–606. https://
doi.org/10.1111/bcp.12635.
[78] Craig DG, Bates CM, Davidson JS, Martin KG, Hayes PC, Simpson KJ. Staggered
overdose pattern and delay to hospital presentation are associated with adverse
outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol
2012;73(2):285–94. https://doi.org/10.1111/j.1365-2125.2011.04067.x.
[79] Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, et al. Efﬁcacy
and safety of paracetamol for spinal pain and osteoarthritis: systematic review
and meta-analysis of randomised placebo controlled trials. BMJ 2015;350:
h1225. https://doi.org/10.1136/bmj.h1225.
[80] Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and non-
alcoholic fatty liver disease: a pathogenic duo. Endocr Rev 2013;34(1):84–129.
https://doi.org/10.1210/er.2012-1009.
[81] Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, et al. Prevalence of nonalcoholic fatty
liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine
2017;96(39):e8179. https://doi.org/10.1097/md.0000000000008179.
[82] Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, et al.
High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabe-
tes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab
2015;100(6):2231–8. https://doi.org/10.1210/jc.2015-1966.
[83] Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver dis-
ease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res 2017;3
(Suppl 1):212–32. https://doi.org/10.18053/jctres.03.2017S1.006.
[84] Michaut A, Moreau C, Robin MA, Fromenty B. Acetaminophen-induced liver injury
in obesity and nonalcoholic fatty liver disease. Liver Int 2014;34(7):e171–9.
https://doi.org/10.1111/liv.12514.
[85] Caparrotta TM, Antoine DJ, Dear JW. Are some people at increased risk of
paracetamol-induced liver injury? A critical review of the literature. Eur J Clin
Pharmacol 2018;74(2):147–60. https://doi.org/10.1007/s00228-017-2356-6.
[86] Ajith TA. Role of mitochondria and mitochondria-targeted agents in non-alco-
holic fatty liver disease. Clin Exp Pharmacol Physiol 2018;45(5):413–21. https://
doi.org/10.1111/1440-1681.12886.
[87] Kon K, Ikejima K, Okumura K, Arai K, Aoyama T, Watanabe S. Diabetic KK-A(y)
mice are highly susceptible to oxidative hepatocellular damage induced by acet-
aminophen. Am J Physiol Gastrointest Liver Physiol 2010;299(2):G329–37.
https://doi.org/10.1152/ajpgi.00361.2009.
[88] Kim YH, Hwang JH, Kim KS, Noh JR, Choi DH, Kim DK, et al. Metformin amelio-
rates acetaminophen hepatotoxicity via Gadd45beta-dependent regulation of
JNK signaling in mice. J Hepatol 2015;63(1):75–82. https://doi.org/10.1016/j.
jhep.2015.02.008.
[89] Du K, Ramachandran A, Weemhoff JL, Chavan H, Xie Y, Krishnamurthy P, et al.
Editor's highlight: metformin protects against acetaminophen hepatotoxicity by
attenuation of mitochondrial oxidant stress and dysfunction. Toxicol Sci
2016;154(2):214–26. https://doi.org/10.1093/toxsci/kfw158.
[90] Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen)
be administered to patients with liver impairment? Br J Clin Pharmacol 2016;81
(2):210–22. https://doi.org/10.1111/bcp.12802.
[91] Kamali F, Thomas SH, Ferner RE. Paracetamol elimination in patients with non-
insulin dependent diabetes mellitus. Br J Clin Pharmacol 1993;35(1):58–61.
[92] Nasri H, Raﬁeian-Kopaei M. Diabetes mellitus and renal failure: prevention and
management. J Res Med Sci: Off J Isfahan Univ Med Sci 2015;20(11):1112–20.
https://doi.org/10.4103/1735-1995.172845.
[93] Pratt N, Roughead EE, Ryan P, Gilbert AL. Differential impact of NSAIDs on rate of
adverse events that require hospitalization in high-risk and general veteran
populations: a retrospective cohort study. Drugs Aging 2010;27(1):63–71.
https://doi.org/10.2165/11531250-000000000-00000.
[94] Roughead EE, Ramsay E, Pratt N, Gilbert AL. NSAID use in individuals at risk of
renal adverse events: an observational study to investigate trends in Australian
veterans. Drug Saf 2008;31(11):997–1003.
[95] Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal
anti-inﬂammatory drugs and risk of ARF in the general population. Am J Kidney
Dis 2005;45(3):531–9. https://doi.org/10.1053/j.ajkd.2004.12.005.
[96] Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL,
et al. Drug interactions between antihypertensive drugs and non-steroidal anti-
inﬂammatory agents: a descriptive study using the French Pharmacovigilance
database. Fundam Clin Pharmacol 2014;28(2):230–5. https://doi.org/10.1111/
fcp.12014.
[97] Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-
inﬂammatory drugs with diuretics and/or renin-angiotensin system inhibitors
in the community increases the risk of acute kidney injury. Kidney Int 2015;88
(2):396–403. https://doi.org/10.1038/ki.2015.101.
[98] Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angio-
tensin converting enzyme inhibitors, and angiotensin receptor blockers with
non-steroidal anti-inﬂammatory drugs and risk of acute kidney injury: nested
case-control study. BMJ 2013;346:e8525. https://doi.org/10.1136/bmj.e8525.
[99] Wong HK, Ong KL, Cheung CL, Cheung BM. Utilization of glucose, blood pressure,
and lipid lowering medications among people with type II diabetes in the United
States, 1999-2010. Ann Epidemiol 2014;24(7):516–21. https://doi.org/10.1016/j.
annepidem.2014.05.001.
[100] Scheen AJ. Pharmacodynamics, efﬁcacy and safety of sodium-glucose co-trans-
porter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Drugs 2015;75(1):33–59. https://doi.org/10.1007/s40265-014-0337-y.
[101] Scheen AJ. SGLT2 inhibitors: beneﬁt/risk balance. Curr Diab Rep 2016;16(10):92.
https://doi.org/10.1007/s11892-016-0789-4.
[102] Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman SN. Can SGLT2
inhibitors cause acute renal failure? plausible role for altered glomerularhemodynamics and medullary hypoxia. Drug Saf 2018;41(3):239–52. https://
doi.org/10.1007/s40264-017-0602-6.
[103] ThomasMC. Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol
Rev 2016;12(3):249–55. https://doi.org/10.2174/1573403X12666160606120254.
[104] Amer M, Bead VR, Bathon J, Blumenthal RS, Edwards DN. Use of nonsteroidal anti-
inﬂammatory drugs in patients with cardiovascular disease: a cautionary tale. Car-
diol Rev 2010;18(4):204–12. https://doi.org/10.1097/CRD.0b013e3181ce1521.
[105] Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonste-
roidal anti-inﬂammatory drugs. Expert Opin Drug Saf 2006;5(1):83–94. https://
doi.org/10.1517/14740338.5.1.83.
[106] Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-
inﬂammatory drug-induced cardiovascular adverse events: a meta-analysis.
J Clin Pharm Ther 2017;42(1):27–38. https://doi.org/10.1111/jcpt.12484.
[107] Nissen SE, Yeomans ND, Solomon DH, Luscher TF, Libby P, Husni ME, et al. Car-
diovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl
J Med 2016;375(26):2519–29. https://doi.org/10.1056/NEJMoa1611593.
[108] Solomon DH, Husni ME, Wolski KE, Wisniewski LM, Borer JS, Graham DY, et al.
Differences in safety of nonsteroidal antiinﬂammatory drugs in patients with
osteoarthritis and patients with rheumatoid arthritis: a randomized clinical trial.
Arthritis Rheumatol 2018;70(4):537–46. https://doi.org/10.1002/art.40400.
[109] Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, et al. The Effects of
cyclooxygenase-2 inhibitors and nonsteroidal anti-inﬂammatory therapy on
24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2
diabetes mellitus. Arch Intern Med 2005;165(2):161–8. https://doi.org/10.1001/
archinte.165.2.161.
[110] Schmidt M, Sorensen HT, Pedersen L. Diclofenac use and cardiovascular risks:
series of nationwide cohort studies. BMJ 2018;362:k3426. https://doi.org/
10.1136/bmj.k3426.
[111] Mazhar F, Haider N, Sultana J, Akram S, Ahmed Y. Prospective study of NSAIDs
prescribing in Saudi Arabia: cardiovascular and gastrointestinal risk in patients
with diabetes mellitus. Int J Clin Pharmacol Ther 2018;56(2):64–71. https://doi.
org/10.5414/cp203071.
[112] Barthel HR, Axford-Gatley RA. Topical nonsteroidal anti-inﬂammatory drugs for
osteoarthritis. Postgrad Med 2010;122(6):98–106. https://doi.org/10.3810/
pgm.2010.11.2227.
[113] Rannou F, Pelletier JP, Martel-Pelletier J. Efﬁcacy and safety of topical NSAIDs in
the management of osteoarthritis: evidence from real-life setting trials and sur-
veys. Semin Arthritis Rheum 2016;45(4 Suppl):S18–21. https://doi.org/10.1016/
j.semarthrit.2015.11.007.
[114] Peniston JH, Gold MS, Wieman MS, Alwine LK. Long-term tolerability of topical
diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comor-
bidities. Clin Interv Aging 2012;7:517–23. https://doi.org/10.2147/CIA.S35416.
[115] Baraf HS, Gold MS, Petruschke RA, Wieman MS. Tolerability of topical diclofe-
nac sodium 1% gel for osteoarthritis in seniors and patients with comorbid-
ities. Am J Geriatr Pharmacother 2012;10(1):47–60. https://doi.org/10.1016/
j.amjopharm.2011.12.002.
[116] Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term
effects of glucosamine sulphate on osteoarthritis progression: a randomised,
placebo-controlled clinical trial. Lancet 2001;357(9252):251–6. https://doi.org/
10.1016/S0140-6736(00)03610-2.
[117] Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucos-
amine sulfate use and delay of progression of knee osteoarthritis: a 3-year, ran-
domized, placebo-controlled, double-blind study. Arch Intern Med 2002;162
(18):2113–23.
[118] Zegels B, Crozes P, Uebelhart D, Bruyere O, Reginster JY. Equivalence of a single
dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin
4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double
blind placebo controlled study. Osteoarthr Cartil 2013;21(1):22–7. https://doi.
org/10.1016/j.joca.2012.09.017.
[119] Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY. Long-term effects
of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthri-
tis progression prevention, a two-year, randomized, double-blind, placebo-con-
trolled trial. Arthritis Rheum 2009;60(2):524–33. https://doi.org/10.1002/
art.24255.
[120] Altman RD, Abramson S, Bruyere O, Clegg D, Herrero-Beaumont G, Maheu E,
et al. Commentary: osteoarthritis of the knee and glucosamine. Osteoarthr Cartil
2006;14(10):963–6. https://doi.org/10.1016/j.joca.2006.06.010.
[121] Maheu E, Cadet C, Marty M, Moyse D, Kerloch I, Coste P, et al. Randomised, con-
trolled trial of avocado-soybean unsaponiﬁable (Piascledine) effect on structure
modiﬁcation in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis 2014;73
(2):376–84. https://doi.org/10.1136/annrheumdis-2012-202485.
[122] Reginster JY. The efﬁcacy of glucosamine sulfate in osteoarthritis: ﬁnancial and
nonﬁnancial conﬂict of interest. Arthritis Rheum 2007;56(7):2105–10. https://
doi.org/10.1002/art.22852.
[123] Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade chondroitin
sulfate is as effective as celecoxib and superior to placebo in symptomatic knee
osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CON-
CEPT). Ann Rheum Dis 2017;76(9):1537–43. https://doi.org/10.1136/annrheum-
dis-2016-210860.
[124] Pavelka K, Bruyere O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al. Diacerein: ben-
eﬁts, risks and place in the management of osteoarthritis. An opinion-based
report from the ESCEO. Drugs Aging 2016;33(2):75–85. https://doi.org/10.1007/
s40266-016-0347-4.
[125] Christiansen BA, Bhatti S, Goudarzi R, Emami S. Management of osteoarthritis
with avocado/soybean unsaponiﬁables. Cartilage 2015;6(1):30–44. https://doi.
org/10.1177/1947603514554992.
N. Veronese et al. / Seminars in Arthritis and Rheumatism 49 (2019) 919 19[126] Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al.
Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev
2009(2):CD002946. https://doi.org/10.1002/14651858.CD002946.pub2.
[127] Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, et al. Effects of
glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or
knee: network meta-analysis. BMJ 2010;341:c4675. https://doi.org/10.1136/
bmj.c4675.
[128] Hathcock JN, Shao A. Risk assessment for glucosamine and chondroitin sul-
fate. Regul Toxicol Pharmacol 2007;47(1):78–83. https://doi.org/10.1016/j.
yrtph.2006.07.004.
[129] Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthri-
tis. Cochrane Database Syst Rev 2015;1:CD005614. https://doi.org/10.1002/
14651858.CD005614.pub2.
[130] Pelletier JP, Martel-Pelletier J. Diacerein-containing products: same risk of diar-
rhoea? Aging Clin Exp Res 2018;30(4):411–2. https://doi.org/10.1007/s40520-
018-0911-3.
[131] Olivier P, Montastruc JL. Reseau francais des centres regionaux de p. [Post-mar-
keting safety proﬁle of avocado-soybean unsaponiﬁables]. Presse Med 2010;39
(10):e211–6. https://doi.org/10.1016/j.lpm.2010.01.013.
[132] Garvey WT, Olefsky JM, Matthaei S, Marshall S. Glucose and insulin co-regulate
the glucose transport system in primary cultured adipocytes. A new mechanism
of insulin resistance. J Biol Chem. 1987;262(1):189–97.
[133] Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating
glucose-induced desensitization of the glucose transport system. Role of hexos-
amine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266
(8):4706–12.
[134] Baron AD, Zhu JS, Zhu JH, Weldon H, Maianu L, Garvey WT. Glucosamine induces
insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle.
Implications for glucose toxicity. J Clin Investig 1995;96(6):2792–801. https://
doi.org/10.1172/JCI118349.
[135] Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P, Tack CJ. Short-term glu-
cosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol
Metab 2001;86(5):2099–103. https://doi.org/10.1210/jcem.86.5.7470.
[136] Monauni T, Zenti MG, Cretti A, Daniels MC, Targher G, Caruso B, et al. Effects of
glucosamine infusion on insulin secretion and insulin action in humans. Diabe-
tes 2000;49(6):926–35.
[137] Muniyappa R, Karne RJ, Hall G, Crandon SK, Bronstein JA, Ver MR, et al. Oral glu-
cosamine for 6 weeks at standard doses does not cause or worsen insulin resis-
tance or endothelial dysfunction in lean or obese subjects. Diabetes 2006;55
(11):3142–50. https://doi.org/10.2337/db06-0714.
[138] Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucos-
amine, chondroitin sulfate, and the two in combination for painful knee
osteoarthritis. N Engl J Med 2006;354(8):795–808. https://doi.org/10.1056/
NEJMoa052771.
[139] Palma Dos Reis R, Giacovelli G, Girolami F, Andre R, Bonazzi A, Rovati LC. Crystal-
line glucosamine sulfate in the treatment of osteoarthritis: evidence of long-
term cardiovascular safety from clinical trials. Open Rheumatol J 2011;5:69–77.
https://doi.org/10.2174/1874312901105010069.
[140] Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Mar-
tin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis
symptoms: a randomized, double-blind, placebo-controlled study using acet-
aminophen as a side comparator. Arthritis Rheum 2007;56(2):555–67. https://
doi.org/10.1002/art.22371.
[141] Dostrovsky NR, Towheed TE, Hudson RW, Anastassiades TP. The effect of
glucosamine on glucose metabolism in humans: a systematic review of the
literature. Osteoarthr Cartil 2011;19(4):375–80. https://doi.org/10.1016/j.
joca.2011.01.007.
[142] Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glu-
cosamine use and effects on glucosemetabolism in normal and diabetic individuals.
DiabetesMetab Res Rev 2011;27(1):14–27. https://doi.org/10.1002/dmrr.1150.
[143] Gommans YMM, Runhaar J, Jacobs ML, Bierma-Zeinstra SMA. The effect of pro-
longed glucosamine usage on HbA1c Levels and new-onset diabetes mellitus in
overweight and obese middle-aged women. Am J Med 2017;130(6):731-7 e6–
737. https://doi.org/10.1016/j.amjmed.2016.11.038. e6.
[144] Runhaar J, Deroisy R, van Middelkoop M, Barretta F, Barbetta B, Oei EH, et al. The
role of diet & exercise and of glucosamine sulfate in the prevention of knee osteoar-
thritis: further results from the Prevention of Knee Osteoarthritis in Overweight
Females (PROOF) study. Semin Arthritis Rheum 2016;45(Suppl 4S):S42–S8.
[145] Mylan. DONA (crystalline glucosamine sulfate1500 mg powder): summary of
product characteristics 2018 2018.
[146] Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol
2009;28(7):749–56. https://doi.org/10.1007/s10067-009-1135-x.
[147] Choudhry MN, Malik RA, Charalambous CP. Blood glucose levels following intra-
articular steroid injections in patients with diabetes: a systematic review. JBJS
Rev 2016;4(3). https://doi.org/10.2106/JBJS.RVW.O.00029.
[148] Cooper C, Bardin T, Brandi M-L, Cacoub P, Caminis J, Civitelli R, et al. Balancing
beneﬁts and risks of glucocorticoids in rheumatic diseases and other inﬂamma-
tory joint disorders: new insights from emerging data. An expert consensus
paper from the European Society for Clinical and Economic Aspects of Osteopo-
rosis and Osteoarthritis (ESCEO). Aging Clin Exp Res 2016;28(1):1–16. https://
doi.org/10.1007/s40520-015-0522-1.
[149] Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efﬁcacy of hyalur-
onic acid in comparison with NSAIDs for knee osteoarthritis: a systematicreview and meta-analysis. Semin Arthritis Rheum 2014;43(5):593–9. https://
doi.org/10.1016/j.semarthrit.2013.10.002.
[150] Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeu-
tic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee
osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 2009;61
(12):1704–11. https://doi.org/10.1002/art.24925.
[151] Bannuru RR, Osani M, Vaysbrot EE, McAlindon TE. Comparative safety proﬁle of
hyaluronic acid products for knee osteoarthritis: a systematic review and net-
work meta-analysis. Osteoarthr Cartil 2016;24(12):2022–41. https://doi.org/
10.1016/j.joca.2016.07.010.
[152] Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Com-
parative effectiveness of pharmacologic interventions for knee osteoarthritis: a
systematic review and network meta-analysis. Ann Intern Med 2015;162
(1):46–54. https://doi.org/10.7326/M14-1231.
[153] Maheu E, Bannuru RR, Herrero-Beaumont G, Allali F, Bard H, Migliore A. Why we
should deﬁnitely include intra-articular hyaluronic acid as a therapeutic option
in the management of knee osteoarthritis: results of an extensive critical litera-
ture review. Semin Arthritis Rheum 2018. https://doi.org/10.1016/j.semar-
thrit.2018.06.002.
[154] Cooper C, Rannou F, Richette P, Bruyere O, Al-Daghri N, Altman RD, et al. Use of
intraarticular hyaluronic acid in the management of knee osteoarthritis in clini-
cal practice. Arthritis Care Res 2017;69(9):1287–96. https://doi.org/10.1002/
acr.23204.
[155] Maheu E, Rannou F, Reginster JY. Efﬁcacy and safety of hyaluronic acid in the
management of osteoarthritis: evidence from real-life setting trials and surveys.
Semin Arthritis Rheum 2016;45(4 Suppl):S28–33. https://doi.org/10.1016/j.
semarthrit.2015.11.008.
[156] Altman R, Lim S, Steen RG, Dasa V. Hyaluronic acid injections are associated with
delay of total knee replacement surgery in patients with knee osteoarthritis:
evidence from a large U.S. health claims database. PLoS One 2015;10(12):
e0145776. https://doi.org/10.1371/journal.pone.0145776.
[157] Chen CP, Hung W, Lin SH. Effectiveness of hyaluronic acid for treating diabetic
foot: a systematic review and meta-analysis. Dermatol Ther 2014;27(6):331–6.
https://doi.org/10.1111/dth.12153.
[158] Wluka AE, Lombard CB, Cicuttini FM. Tackling obesity in knee osteoarthritis. Nat
Rev Rheumatol 2013;9(4):225–35. https://doi.org/10.1038/nrrheum.2012.224.
[159] Springer BD, Carter JT, McLawhorn AS, Scharf K, Roslin M, Kallies KJ, et al. Obe-
sity and the role of bariatric surgery in the surgical management of osteoarthri-
tis of the hip and knee: a review of the literature. Surg Obes Relat Dis 2017;13
(1):111–8. https://doi.org/10.1016/j.soard.2016.09.011.
[160] Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Meta-
bolic surgery in the treatment algorithm for type 2 diabetes: a joint statement
by international diabetes organizations. Diabetes Care 2016;39(6):861–77.
https://doi.org/10.2337/dc16-0236.
[161] Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL. Metabolic sur-
gery: weight loss, diabetes, and beyond. J Am Coll Cardiol 2018;71(6):670–87.
https://doi.org/10.1016/j.jacc.2017.12.014.
[162] Lindegaard KK, Jorgensen NB, Just R, Heegaard PM, Madsbad S. Effects of Roux-
en-Y gastric bypass on fasting and postprandial inﬂammation-related parame-
ters in obese subjects with normal glucose tolerance and in obese subjects with
type 2 diabetes. Diabetol Metab Syndr 2015;7:12. https://doi.org/10.1186/
s13098-015-0012-9.
[163] Haﬁda S, Mirshahi T, Nikolajczyk BS. The impact of bariatric surgery on inﬂam-
mation: quenching the ﬁre of obesity? Curr Opin Endocrinol Diabetes Obes
2016;23(5):373–8. https://doi.org/10.1097/MED.0000000000000277.
[164] Yadav R, Hama S, Liu Y, Siahmansur T, Schoﬁeld J, Syed AA, et al. Effect of Roux-
en-Y bariatric surgery on lipoproteins, insulin resistance, and systemic and vas-
cular inﬂammation in obesity and diabetes. Front Immunol 2017;8:1512.
https://doi.org/10.3389/ﬁmmu.2017.01512.
[165] Gallo G, Candilio G, De Luca E, Iannicelli A, Sciaudone G, Pellino G, et al. Bar-
iatric surgery and rheumatic diseases: a literature review. Rev Recent Clin
Trials 2018;13(3):176–83. https://doi.org/10.2174/157488711366618031
4095445.
[166] Groen VA, van de Graaf VA, Scholtes VA, Sprague S, van Wagensveld BA, Pool-
man RW. Effects of bariatric surgery for knee complaints in (morbidly) obese
adult patients: a systematic review. Obes Rev 2015;16(2):161–70. https://doi.
org/10.1111/obr.12236.
[167] King WC, Chen JY, Belle SH, Courcoulas AP, Dakin GF, Elder KA, et al. Change in
pain and physical function following bariatric surgery for severe obesity. JAMA
2016;315(13):1362–71. https://doi.org/10.1001/jama.2016.3010.
[168] Smith TO, Aboelmagd T, Hing CB, MacGregor A. Does bariatric surgery prior to
total hip or knee arthroplasty reduce post-operative complications and
improve clinical outcomes for obese patients? Systematic review and meta-
analysis. Bone Joint J 2016;98-B(9):1160–6. https://doi.org/10.1302/0301-
620X.98B9.38024.
[169] Nearing EE 2nd, Santos TM, Topolski MS, Borgert AJ, Kallies KJ, Kothari SN. Bene-
ﬁts of bariatric surgery before elective total joint arthroplasty: is there a role for
weight loss optimization? Surg Obes Relat Dis 2017;13(3):457–62. https://doi.
org/10.1016/j.soard.2016.11.005.
[170] Hooper JM, Deshmukh AJ, Schwarzkopf R. The role of bariatric surgery in the
obese total joint arthroplasty patient. Orthop Clin N Am 2018;49(3):297–306.
https://doi.org/10.1016/j.ocl.2018.02.003.
